BRAF and cardiac hypertrophy: Such drugs seem unlikely to have overt on-target cardiotoxic effects in patients without cardiovascular complications (since cardiomyocyte BRAF knockout alone did not affect cardiac function and dimensions), although there may be some risk for patients with underlying cardiac hypertrophy that requires BRAF signalling.